Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Alleviate Peritoneal Dialysis-Associated Peritoneal Injury
- 1 April 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Stem Cells and Development
- Vol. 32 (7-8), 197-211
- https://doi.org/10.1089/scd.2022.0244
Abstract
Peritoneal fibrosis is a critical sequela that limits the application of peritoneal dialysis (PD). This study explored the role and mechanism of bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) in preventing PD-associated peritoneal injury. C57BL/6 mice were randomized into three groups: a control (saline), peritoneal injury (2.5% glucose peritoneal dialysate + lipopolysaccharide (LPS)), and peritoneal injury + exosome group. After six weeks, mice were dissected, and the parietal peritoneum was collected. The level of peritoneal structural and functional damage was assessed. Additionally, transcriptome analysis of the peritoneum and miRNA sequencing on BMSC-Exos were performed. The parietal peritoneum had significantly thickened, and peritoneal function was impaired in the peritoneal injury group. Peritoneal structural and functional damage was significantly reduced after exosome treatment, while peritoneal inflammation, fibrosis, angiogenesis, and mesothelial damage significantly increased. Transcriptomic analysis showed that the BMSC-Exos affected the cell cycle process, cell differentiation, and inflammatory response regulation. Significant pathways in the exosome group were enriched by inflammation, immune response, and cell differentiation, which constitute a molecular network that regulates the peritoneal protective mechanism. Additionally, inflammatory factors (TNF-α, IL-1β), fibrosis markers (α-SMA, collagen-III, fibronectin), profibrotic cytokines (TGF-β1), and angiogenesis-related factor (VEGF) were downregulated at the mRNA and protein levels through BMSC-Exos treatment. BMSC-Exos treatment can prevent peritoneal injury by inhibiting peritoneal fibrosis, inflammation, and angiogenesis, showing a multi-target regulatory effect. Therefore, BMSC-Exos therapy might be a new therapeutic strategy for treating peritoneal injury.Keywords
This publication has 115 references indexed in Scilit:
- MiR-335-5p Promotes Chondrogenesis in Mouse Mesenchymal Stem Cells and Is Regulated Through Two Positive Feedback LoopsJournal of Bone and Mineral Research, 2013
- Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signalingKidney International, 2013
- Sox9-Regulated miRNA-574-3p Inhibits Chondrogenic Differentiation of Mesenchymal Stem CellsPLOS ONE, 2013
- Therapeutic Potential of Mesenchymal Stem Cells in Regenerative MedicineStem Cells International, 2013
- Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in CanadaNephrology Dialysis Transplantation, 2012
- Therapeutic potential of bone marrow-derived mesenchymal stem cells for cutaneous wound healingFrontiers in Immunology, 2012
- Pleiotrophin triggers inflammation and increased peritoneal permeability leading to peritoneal fibrosisKidney International, 2012
- Adipogenic differentiation of human mesenchymal stromal cells is down‐regulated by microRNA‐369‐5p and up‐regulated by microRNA‐371Journal of Cellular Physiology, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Nitric oxide synthase isoforms play distinct roles during acute peritonitisNephrology Dialysis Transplantation, 2009